


Pharmaeconomica BV Revenue
Biotechnology Research • Ostend, Flemish Region, Belgium • 1-10 Employees
Pharmaeconomica BV revenue & valuation
| Annual revenue | $342,220 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,100,000 |
| Total funding | No funding |
Key Contact at Pharmaeconomica BV
Kanzal Iman
Co-Founder and Director
Company overview
| Headquarters | Ostend, Flemish Region, Belgium |
| Website | |
| NAICS | 541714 |
| SIC | 824 |
| Keywords | Biotech, Market Access, Pricing, Machine Learning, Mathematical Modeling, Medtech, Heor, Health Economic Evaluations, Value Communication, Statistical Modeling, Evidence Synthesis, Network Meta-Analysis, Systematic Literature Reviews, Indirect Treatment Comparison, Early Value Assessment, Infectious Disease Modeling, Ai-Driven Drug Discovery Platform, Ai-Driven Drug Discovey, Insilico Drug Discovery, Peptide Extension Approach |
| Founded | 2023 |
| Employees | 1-10 |
| Socials |
About Pharmaeconomica BV
Pharmaeconomica, headquartered in Belgium, pioneers AI-driven small-molecule drug discovery. Our innovative approach integrates cutting-edge AI technology, revolutionizing traditional processes to accelerate steps, enhance efficiency, and slash costs associated with experiments. By minimizing the need for physical experiments, our AI-driven platform optimizes discovery tasks like molecule design and testing, ensuring effective validation of results. Innovating Drug Discovery with Pharmaeconomica At Pharmaeconomica, we're at the forefront of drug discovery innovation. With a seasoned team, we prioritize solutions for therapeutic areas with high unmet medical needs, driving groundbreaking advancements in the field. Revolutionary ML Platform for Identifying AD Inhibitors Powered by machine learning, our proprietary platform swiftly analyzes extensive datasets, uncovering novel drug candidates with unrivaled efficiency. Focused on Alzheimer's disease, we're committed to identifying inhibitors that target its complex nature, aiming to enhance patient outcomes significantly. Empirical Evidence and Theoretical Models Supporting Our Platform Our platform shows promising results, surpassing traditional methods in identifying potential AD inhibitors. Computational models forecast substantial reductions in key markers of Alzheimer's progression, underlining our platform's potential impact. Beyond Alzheimer's: A Versatile Platform for Drug Discovery While Alzheimer's remains our initial focus, our adaptable platform enables swift adaptation to other disease targets. Continuously enhancing our capabilities, we actively seek partnerships to propel the future of personalized medicine.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
Pharmaeconomica BV has never raised funding before.
Pharmaeconomica BV Tech Stack
Discover the technologies and tools that power Pharmaeconomica BV's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Issue trackers
Appointment scheduling
PaaS
Blogs
Miscellaneous
Programming languages
Miscellaneous
Security
JavaScript frameworks
Blogs
IaaS
Frequently asked questions
4.8
40,000 users



